StockNews.com began coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Get Rating) in a report published on Tuesday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.
Separately, Alliance Global Partners assumed coverage on Akari Therapeutics in a research report on Tuesday, November 1st. They set a buy rating and a $4.00 price target for the company.
Akari Therapeutics Price Performance
AKTX stock opened at $0.53 on Tuesday. The firm has a market capitalization of $39.46 million, a PE ratio of -1.51 and a beta of 1.28. Akari Therapeutics has a 1 year low of $0.38 and a 1 year high of $1.67. The business has a 50 day simple moving average of $0.54 and a 200-day simple moving average of $0.89.
Institutional Trading of Akari Therapeutics
Hedge funds and other institutional investors have recently made changes to their positions in the company. Armistice Capital LLC purchased a new position in shares of Akari Therapeutics during the third quarter worth about $2,703,000. Omnia Family Wealth LLC lifted its position in shares of Akari Therapeutics by 13.7% during the 1st quarter. Omnia Family Wealth LLC now owns 758,144 shares of the biopharmaceutical company’s stock valued at $910,000 after acquiring an additional 91,059 shares during the period. Finally, LPL Financial LLC acquired a new position in shares of Akari Therapeutics during the 2nd quarter worth approximately $83,000. Institutional investors and hedge funds own 2.83% of the company’s stock.
About Akari Therapeutics
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid.
- Get a free copy of the StockNews.com research report on Akari Therapeutics (AKTX)
- Ford Revving Up Production Of EV Power Units At U.K. Plant
- Are the Short Sellers Still Right About Mullen Automotive stock?
- La-Z-Boy Reclines To More Comfortable Levels
- Is The Recovery Rally Here For SoFi?
- Is Apple Going To Rally Into Year End?
Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.